The impact of emicizumab on the clinical validation of new therapies for haemophilia A

Documenti analoghi

• Haemophilic Elbow Arthropathy: Mechanisms, Management and Future Perspectives
  di: Sébastien Lobet, et al.
  Pubblicazione: (2025)
• Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries
  di: Pier Mannuccio Mannucci, et al.
  Pubblicazione: (2024)
• Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience
  di: Robert Klamroth, et al.
  Pubblicazione: (2024)
• Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding
  di: Cedric Hermans, et al.
  Pubblicazione: (2024)
• Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
  di: Christian Pfrepper, et al.
  Pubblicazione: (2024)